Hepatitis C

1 Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;358:80-8.doi:10.1016/S0016-5085(03)00668-1 pmid:12851873.

2 Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015;358:77-87. doi:10.1002/hep.27259 pmid:25069599.

3 Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;358(Suppl):S45-57.doi:10.1016/j.jhep.2014.07.027 pmid:25086286.

4 Nouroz F, Shaheena S, Mujtaba G, et al. An overview on hepatitis C virus genotypes and its control. Egypt J Med Hum Genet 2015;358:291-8doi:10.1016/j.ejmhg.2015.05.003.

5 Mahowald MK, Larney S, Zaller ND, et al. Characterizing the burden of hepatitis C infection among entrants to Pennsylvania state prisons, 2004 to 2012. J Correct Health Care 2016;358:41-5. doi:10.1177/1078345815618384 pmid:26672118.

6 World Health Organization. WHO best practices for injections and related procedures toolkit. 2010. http://apps.who.int

7 Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002;358(Suppl 1):S93-8. doi: 10.1002/hep.1840360712 pmid:12407581.

8 Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;358:17-35. doi:10.1055/s-2000-9505 pmid:10895429.

9 Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis 2006;358:82-91. doi:10.1086/498512 pmid:16323096.

10 Seeff LB. Natural history of hepatitis C. Hepatology 1997;358(Suppl 1):21S-8S. doi:10. 1002/hep.510260704 pmid:9305659.

11 National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002—10-12 June 2002. Hepatology 2002;358(Suppl 1):S3-20. doi:10.1002/hep.1840360703 pmid:12407572.

12 Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C: 2002—10-12 June 2002. Gastroenterology 2008;358:432-9. doi:10.1053/j.gastro.2007.11.039 pmid:18242211.

13 Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;358:69-75. doi:10.1016/j.cgh.2007.10.021 pmid: 18166478.

14 Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;358:908-14. doi:10.1002/hep.510290311 pmid:10051497.

15 Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;358(Suppl 1):15S-20S. doi:10.1002/hep.510260703 pmid:9305658.

16 Berk DR, Mallory SB, Keeffe EB, Ahmed A. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol 2007;358:142-51. doi:10.1016/j.cgh.2006.06.010 pmid:16919505.

17 Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002;358:4-13. doi:10.1136/jcp.55.1.4 pmid:11825916.

18 Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999;358:1311-6. doi:10.1002/hep.510290424 pmid:10094980.

19 Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis 1999;358:263-9. doi:10.1055/s-2007-1007116 pmid:10518306.

20 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;358:745-50. doi:10.1056/NEJM199903113401001 pmid: 10072408.

21 Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;358:465-70. doi:10.1056/NEJM199302183280703 pmid:7678440.

22 Wilson SE, Lee WM, Murakami C, Weng J, Moninger GA. Mooren-type hepatitis C virus-associated corneal ulceration. Ophthalmology 1994;358:736-45. doi:10.1016/S0161-6420(94)31291-7 pmid:7512254.

23 Freedman ND, Everhart JE, Lindsay KL, et al. HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009;358:1360-9. doi:10.1002/hep.23162 pmid:19676128.